

Medicine Made to Measure




Modern medicine seeks to personalize diagnosis and treatment to the needs of individual patients. This need is heightened in particular for those individual patients where no treatments are available. The ultimate goal of MMM is to go even beyond the latest genetic medicine approaches, implementing a novel paradigm of treatment development: the field of single patient tailored antisense oligonucleotide (ASO) treatments for patients with nano-rare disease mutations. MMM develops core modules of a novel “out-of-the-box”, but still EMA-advised treatment development path for these patients – from omics-based theranostics, via preclinical target validation to innovative trial methodology and a pioneering ethical framework for individualised genetic therapies.

MMM also provides a unique opportunity for doctoral candidates to be involved in building – and to receive training – in all core modules needed for tailored ASO treatment in Europe.



Funded by the EU's *Horizon Europe* Marie Skłodowska-Curie Actions scheme,
GA no. 101120256.



Our consortium consists of world-leading experts and partners with extended experience and relevant know-how in molecular biology, neurology, translational medicine, biochemistry, bioinformatics, philosophy, mathematics, regulatory science and engineering.

- Universitätsklinikum Heidelberg, Germany (WP1.1)
- BianoGMP GmbH, Gera, Germany (WP1.2)
- Ludwig-Maximilians-Universität München, Germany (WP1.3)
- Eberhard Karls Universität Tübingen, Germany (WP2.1)
- Leiden University Medical Center, The Netherlands (WP2.2, WP2.4)
- Biotalentum Tudasfejlesztő Kft, Gödöllő, Hungary (WP2.3)
- mHealth Technologies, Bologna, Italy (WP3.1)
- University of Cambridge, United Kingdom (WP3.2)
- Uppsala Universitet, Sweden (WP3.3)



Website: <https://medicine-made-to-measure.eu>